L4&5 DNA Replication, DNA Mutations, and DNA Repair Systems

Genome Structure and Chromosomal Organization

• Genome Definition: The complete set of genetic material in an organism.

• Human Ploidy: Human somatic cells are diploid ($2n$), containing two copies of each chromosome:

  • $22$ pairs of autosomal chromosomes.

  • $1$ pair of sex-specific chromosomes ($XX$ in females, $XY$ in males).

• Genomic Architecture:

  • Genomic DNA consists of functional genes separated by non-coding intergenic regions.

  • The structural hierarchy progresses from the DNA double helix to chromatin fibers, condensed chromosomes, and the complete karyotype.

• DNA Chemical Directionality:

  • The DNA double helix is antiparallel and directional.

  • Composed of a repeating sugar-phosphate backbone (deoxyribose-phosphate) linked to nitrogenous DNA bases.

  • Each strand runs in a $5' \rightarrow 3'$ direction defined by terminal chemical groups: a $5'$ phosphate group ($5'\text{P}$) at one end and a $3'$ hydroxyl group ($3'\text{OH}$) at the other.

• Clinical and Biological Significance:

  • Variations or alterations in genomic information alter cellular function and predispose individuals to disease.

  • Genome-Wide Association Studies (GWAS) identify specific genetic locus variations associated with common and complex diseases.

  • Genomic alterations account for congenital diseases, arise as de novo mutations, or promote genomic instability leading to cancer.

  • Key pathological conditions linked to DNA alterations include:

    • Sickle Cell Anemia

    • Cystic Fibrosis

    • Philadelphia Chromosome Translocation

    • Charcot-Marie-Tooth Disease

    • Lynch Syndrome

    • Xeroderma Pigmentosum

    • $BRCA1$ and $BRCA2$-related Cancers

Eukaryotic DNA Replication

The Cell Cycle and DNA Content Dynamics

• Cell Cycle Definition: An ordered series of events through which a cell duplicates its genetic genome and divides into two genetically identical daughter cells.

• Phases and DNA Content ($C$):

  • $G_1$ Phase (Gap 1): Cell growth occurs. Diploid state ($2n$) with a DNA content of $2C$.

  • $S$ Phase (Synthesis): Active DNA replication occurs. Cellular DNA content transitions continuously from $2C$ to $4C$.

  • $G_2$ Phase (Gap 2): Post-replication quality control and preparation for division. DNA content is $4C$.

  • $M$ Phase (Mitosis): Chromosome segregation and cell division reduce DNA content from $4C$ back to $2C$ per resulting daughter cell.

Initiation of DNA Replication

• Semi-Conservative Mechanism: Parental DNA strands separate ("melt") and serve as templates for the synthesis of complementary daughter strands, yielding two double helices each containing one original parental strand and one newly synthesized strand.

• Origins of Replication (ORI):

  • Human chromosomes contain approximately $30,000$ to $50,000$ origins of replication scattered across the genome to enable complete replication during $S$ phase.

  • Origin Recognition Complex (ORC): A 6-subunit protein complex bound to ORIs throughout the cell cycle, serving as a platform for recruiting downstream replication proteins.

  • MCM DNA Helicase: Heterohexameric complex recruited to ORIs by the ORC during $G_1$ phase to assemble the Pre-Replicative Complex (pre-RC).

• Fork Formation and Bidirectionality:

  • At $S$ phase onset, MCM helicases are activated to unwind and melt the double-stranded DNA double helix.

  • Two active replication forks are established at each origin, moving bidirectionally away from the ORI as helicases translocate along template strands toward their $5'$ ends.

Elongation Mechanics and Enzymes

• Fundamental Properties of DNA Polymerases:

  1. Unidirectionality: Synthesizes DNA exclusively in the $5' \rightarrow 3'$ direction by adding dNTPs to the free $3'\text{OH}$ end of a growing strand.

  2. Primer Dependency: Cannot initiate DNA synthesis de novo; requires an existing RNA or DNA primer.

  3. Proofreading Activity: Possesses an intrinsic $3' \rightarrow 5'$ exonuclease domain that detects and removes incorrectly incorporated bases.

• Leading Strand vs. Lagging Strand Synthesis:

  • Leading Strand: Oriented $3' \rightarrow 5'$ relative to the direction of replication fork movement. Allows continuous $5' \rightarrow 3'$ synthesis toward the advancing fork following a single RNA priming event by DNA Primase.

  • Lagging Strand: Oriented $5' \rightarrow 3'$ relative to fork movement. Continuous synthesis is impossible; replication proceeds discontinuously away from the fork in short segments termed Okazaki fragments.

• Steps in Lagging Strand Elongation:

  1. Priming: DNA Primase synthesizes short RNA primers periodically along the exposed template strand.

  2. Extension: DNA Polymerase extends the primer $5' \rightarrow 3'$ to produce an Okazaki fragment.

  3. Primer Removal and Gap Filling: RNA primers are excised and filled with complementary DNA nucleotides by DNA Polymerase $\text{δ}$.

  4. Ligation: DNA Ligase catalyzes the formation of phosphodiester bonds to covalently seal adjacent Okazaki fragments.

• Auxiliary Replication Proteins:

  • DNA Topoisomerases: Relieve positive supercoiling and torsional strain generated ahead of the advancing replication fork by inducing transient single- or double-strand nicks in the DNA backbone.

    • DNA Topoisomerase I: Cuts a single strand of DNA; operates via an ATP-independent mechanism.

    • DNA Topoisomerase II: Cuts both strands of DNA; operates via an ATP-dependent mechanism.

  • Single-Strand DNA-binding (SSB) Proteins: Bind selectively to exposed single-stranded DNA on leading and lagging templates to prevent single strands from re-annealing or forming secondary hairpin structures. They are displaced by DNA polymerase during elongation.

Replication of Telomeres and the End-Replication Problem

• The End-Replication Problem:

  • Linear eukaryotic chromosomes cannot fully replicate the extreme $3'$ end of the lagging strand template.

  • Removal of the final RNA primer at the chromosome end leaves an unfillable gap of approximately $100$\,base pairs (historically modeled as a $\approx 12$\,bp gap).

  • This incomplete replication leads to progressive telomere shortening of approximately $100$\,base pairs per cell division cycle.

• Replicative Senescence:

  • After approximately $50$ to $70$ cell divisions (the Hayflick limit), critical loss of repetitive telomeric DNA triggers irreversible cell cycle arrest (senescence) or apoptosis to prevent loss of essential coding genetic material.

• Telomere Structure: Repetitive non-coding DNA sequences consisting of human hexameric repeats $(\text{AGGGTTA})_n$ located at the physical ends of chromosomes.

• Telomerase Function and Mechanism:

  • Telomerase: A specialized ribonucleoprotein reverse transcriptase enzyme complex carrying an integral RNA molecule that serves as an internal template.

  • Extension Process:

    1. Telomerase binds to the exposed $3'$ overhang of the telomeric template strand.

    2. It reverse transcribes its internal RNA template to synthesize complementary $5' \rightarrow 3'$ DNA extensions ($\text{AGGGTTA}$ repeats) onto the $3'$ end.

    3. DNA Primase utilizes the elongated strand as a template to lay down an RNA primer.

    4. DNA Polymerase completes the complementary replication of the lagging strand $3'$ end.

• Expression in Immortalized Cells:

  • Telomerase is repressed in differentiated somatic cells but highly expressed in germ cells, stem cells, and cancer cells.

  • Maintenance of telomere length prevents senescence, granting unlimited replicative potential ("immortality").

  • Historical Example: HeLa cells, isolated in 1951 from a cervical cancer biopsy of Henrietta Lacks ($1920–1951$), express high telomerase activity and represent the first continuously cultured human cell line.

Pharmacological Inhibitors of DNA Replication

• Therapeutic Goal: Halt the cell cycle, restrict hyperproliferative growth, and trigger cell death in malignant tumors, bacterial pathogens, or viral infections.

• Major Classes of Replication Inhibitors:

*   **Inhibitors of dNTP Precursor Synthesis:** Antimetabolites that deplete nucleoside triphosphate pools (e.g., **Methotrexate**, **5-Fluorouracil [5-FU]**).
*   **Intercalating Agents:** Compounds that insert into the double helix, stalling replication forks (e.g., **Cisplatin**, **Bleomycin**).
*   **DNA Polymerase Inhibitors:** Nucleoside/nucleotide analogs that terminate chain elongation (e.g., **Acyclovir**, **Cytarabine**, **Zidovudine [AZT]**).
*   **DNA Topoisomerase Inhibitors:** Agents that stabilize DNA-topoisomerase cleavage complexes, causing lethal strand breaks:
    *   *Antibiotics:* **Quinolones** (inhibit bacterial DNA gyrase/topoisomerase).
    *   *Anti-cancer drugs:* **Irinotecan**, **Topotecan** (inhibit human Topoisomerase I).

DNA Damage and Mutations

Endogenous and Exogenous DNA Damage

• Endogenous DNA Damage: Damage arising from internal physiological processes and chemical instability:

  • Unrepaired errors committed by DNA polymerase proofreading mechanisms.

  • Spontaneous chemical lesions, such as depurination (cleavage of the $N$-glycosidic bond releasing an Adenine or Guanine base, creating an abasic site).

  • Basal Mutation Rate: Quantified at approximately $1 \times 10^{-8}$ mutations per nucleotide per cell division (a probability of $1$ in $100\text{ million}$ per base per generation).

• Exogenous DNA Damage: Damage caused by environmental physical or chemical agents:

  • Ionizing Radiation (X-rays, Gamma rays, high-energy particles): Induces single-strand breaks (SSBs), double-strand breaks (DSBs), and oxidative base lesions.

  • Non-Ionizing Radiation (UV Light): Causes direct photochemical modifications, predominantly pyrimidine dimers (e.g., Thymine-Thymine dimers) and single-strand breaks.

  • Environmental Genotoxins (PAHs, Formaldehyde, Heavy Metals): Promote base oxidation, covalent DNA adduct formation, crosslinking, and intercalative damage.

Mutation Definitions and Classifications

• DNA Mutation: A rare, permanent modification in the DNA sequence present at a frequency below $1\%$ in a population (e.g., mutations in $CFTR$ causing Cystic Fibrosis).

• DNA Polymorphism: A common, stable genetic sequence variation present at a frequency above $1\%$ in a population (e.g., $ABO$ blood group allele variants).

Small-Scale Mutations

Small-scale mutations alter one or a few nucleotide pairs.

• Point Mutations (Base-Pair Substitutions):

  • Silent Mutation: Substitution alters a codon to a synonymous codon encoding the identical amino acid; no change in protein sequence or function.

  • Missense Mutation: Substitution alters a codon to encode a different amino acid, altering primary polypeptide structure.

  • Nonsense Mutation: Substitution transforms an amino acid-encoding codon into a premature STOP codon ($UAA$, $UAG$, or $UGA$), resulting in a truncated, non-functional protein.

• Insertions and Deletions (Indels):

  • Indels Not Divisible by 3: Induce a Frameshift Mutation, altering the downstream translational reading frame and altering the amino acid sequence, often creating premature stop codons.

  • Indels Divisible by 3: Results in an In-Frame Addition or Deletion of one or more amino acids without disrupting the downstream reading frame.

• Splicing Mutations:

  • Mutations located at conserved intron-exon donor ($5'$) or acceptor ($3'$) splice sites in pre-mRNA.

  • Pathological outcomes include exon skipping, intron retention, or activation of cryptic splice sites.

• Promoter and Enhancer Mutations:

  • Occur within non-coding transcriptional regulatory regions.

  • Disrupt binding of General Transcription Factors or RNA Polymerase II, causing abnormal increases or decreases/loss of gene expression.

Clinical Pathologies of Small-Scale Mutations

• Sickle Cell Anemia (SCA):

  • Molecular Mechanism: Caused by a single nucleotide missense mutation in the $\beta$-globin ($HBB$) gene substituting Glutamic Acid with Valine ($\text{Glu} \rightarrow \text{Val}$).

  • Pathophysiology: Under hypoxic conditions, mutant Deoxyhemoglobin S ($\text{HbS}$) exposes a hydrophobic patch, driving hemoglobin polymerization into long rigid fibers that distort red blood cells into a sickle shape.

• Cystic Fibrosis (CF):

  • Genomic Characteristics: Caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator ($CFTR$) gene located on chromosome 7 (spanning $190$\,kb, yielding a $6.2$\,kb mRNA and a $1,480$\,amino acid protein).

  • Mutational Spectrum: Over $2,075$ individual $CFTR$ gene variants identified, comprising missense ($\approx 40\%$), frameshift, splicing, nonsense, and in-frame deletions (such as $\Delta\text{F508}$).

  • Pathophysiology: Impaired epithelial chloride ion transport decreases fluid secretion, producing thick, sticky mucus that obstructs pulmonary airways and exocrine organs.

Large-Scale Mutations (Chromosomal Rearrangements)

• Types of Structural Rearrangements: Large-scale genomic alterations ranging from several kilobases ($\text{kb}$) to full chromosomal arms:

  • Deletions (Micro/Macro): Loss of genomic segments.

  • Duplications: Gain of redundant genomic segments.

  • Translocations: Reciprocal or non-reciprocal exchange of segments between non-homologous chromosomes.

  • Inversions: $180^∘$ end-to-end reversal of an internal chromosome segment.

• Functional Consequences:

  • Gene Disruption: Breakpoints occurring within coding exons abolish protein expression.

  • Gene Amplification: Over-duplication of oncogenic loci.

  • Aberrant Replication / Position Effects: Relocation of genes near heterochromatin or strong enhancers altering baseline expression.

  • Gene Fusion: Translocation fusing portions of two distinct genes to form an chimeric protein.

Clinical Pathologies of Large-Scale Mutations

• Philadelphia Chromosome:

  • Molecular Mechanism: A reciprocal translocation between chromosomes 9 and 22, designated $t(9;22)(q34;q11)$.

  • Fuses the $ABL$ proto-oncogene (tyrosine kinase) on chromosome 9 with the $BCR$ gene on chromosome 22, generating the $BCR::ABL$ fusion gene.

  • Clinical Outcome: Produces a constitutively active, unregulated chimeric tyrosine kinase driving uncontrolled cellular proliferation in Chronic Myeloid Leukemia (CML) ($95\%$ of cases), Acute Lymphoblastic Leukemia (ALL), and Acute Myeloid Leukemia (AML).

• Charcot-Marie-Tooth Disease (CMT):

  • Molecular Mechanism: Large-scale tandem duplication of the Peripheral Myelin Protein 22 ($PMP22$) gene locus on chromosome 17.

  • Pathophysiology: Gene dosage imbalance overexpresses PMP22, destabilizing peripheral nerve myelin sheaths and producing a hereditary motor and sensory neuropathy characterized by progressive distal muscle weakness, tissue wasting, and sensory loss.

DNA Repair Systems

Overview and Tumor Suppressor Networks

• Biological Imperative: Continuous exposure to endogenous metabolism and environmental mutagenic agents requires multiple dedicated DNA repair pathways.

• Cancer Pathogenesis: Congenital or acquired deficiencies in DNA repair proteins cause an accumulation of genome-wide mutations, leading to activation of proto-oncogenes and inactivation of tumor-suppressor genes.

DNA Mismatch Repair (MMR)

• Target Lesions: Corrects single base-base mismatches and small insertion/deletion loops that escape DNA polymerase proofreading during $S$ phase replication.

• Mechanism Steps:

  1. Mismatch Recognition: Protein heterodimers $MSH2$/$MSH6$ and $MLH1$ bind selectively to the un-parental mismatched DNA segment.

  2. Excision: Endonuclease $PMS2$ introduces single-strand nicks on the newly synthesized, error-containing strand, followed by exonuclease degradation of the mismatched region.

  3. Resynthesis: DNA Polymerase fills the gap using the unmodified parental strand as a template, and DNA Ligase seals the remaining nick.

• Pathology – Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer / HNPCC):

  • Etiology: Autosomal dominant germline mutations in MMR genes ($MLH1$, $MSH2$, $MSH6$, or $PMS2$).

  • Lifetime Malignancy Risks:

    • Bowel/Colorectal Cancer: $30\% - 75\%$

    • Womb/Endometrial Cancer: $25\% - 60\%$

    • Ovarian Cancer: $6\% - 14\%$

    • Stomach Cancer: $2\% - 13\%$

    • Urinary Tract Cancer: $2\% - 11\%$

Base Excision Repair (BER)

• Target Lesions: Repairs small, non-helix-distorting base alterations:

  • Abasic (AP) sites generated by spontaneous depurination.

  • Uracil incorporated into DNA via spontaneous deamination of Cytosine.

  • Oxidized bases generated by reactive oxygen species (e.g., 8-oxo-Guanine).

  • Single-strand DNA breaks (SSBs).

• Mechanism Steps:

  1. Recognition: $PARP1$ recognizes single-strand breaks or modified sites.

  2. Base Excision: A specific DNA Glycosylase cleaves the $N$-glycosidic bond joining the damaged base to the sugar backbone, generating an abasic (AP) site.

  3. Endonucleolytic Cleavage: AP Endonuclease cleaves the phosphodiester backbone at the AP site to yield a single-strand break.

  4. Gap Synthesis and Ligation: DNA Polymerase inserts the correct replacement nucleotide, and DNA Ligase seals the nick.

• Therapeutic Target – PARP Inhibitors in Cancer:

  • Pharmacological PARP inhibitors (e.g., Olaparib, Rucaparib, Niraparib) trap PARP1 proteins on damaged DNA bases, preventing completion of BER.

  • Unrepaired single-strand breaks encounter advancing replication forks during $S$ phase, converting them into double-strand breaks (DSBs).

Nucleotide Excision Repair (NER)

• Target Lesions: Repairs bulky, double-helix distorting DNA lesions:

  • Thymine-Thymine (pyrimidine) dimers induced by solar UV radiation.

  • Covalent bulky chemical adducts generated by intercalating agents or Polycyclic Aromatic Hydrocarbons (PAHs).

• Pathophysiological Risk: Unrepaired bulky lesions physically block advancing replication forks, stalling DNA polymerases and forcing either error-prone bypass or collapse into double-strand breaks.

• Mechanism Steps:

  1. Distortion Recognition: Multi-protein complexes (encoded by over $40$ genes) recognize local helical strain.

  2. Unwinding: DNA Helicases locally unwind the damaged region to form a open DNA bubble.

  3. Dual Incision: Dual endonucleases excise an oligonucleotide fragment ($\approx 24 - 32$ nucleotides in length) containing the bulky lesion.

  4. Synthesis and Ligation: DNA Polymerase synthesizes new DNA using the intact complementary strand as a template; DNA Ligase seals the remaining nick.

• Pathology – Xeroderma Pigmentosum (XP):

  • Etiology: Autosomal recessive mutations in core NER genes ($XPA$, $XPB$, $XPC$, $XPD$, $XPE$, or the error-prone bypass polymerase $POLH$).

  • Epidemiology: High prevalence in specific populations, such as India ($1$ in $370$ births), compared to the United States ($1$ in $250,000$).

  • Clinical Manifestations: Complete inability to repair UV-induced pyrimidine dimers, extreme photosensitivity, severe cutaneous freckling, dry skin, and a high risk of developing skin malignancies (basal cell carcinoma, squamous cell carcinoma, melanoma).

Double Strand Break Repair (DSBR)

Double-strand breaks (DSBs) represent catastrophic DNA damage induced by ionizing radiation, reactive oxygen species (ROS), or collapsed replication forks. Unrepaired DSBs induce severe genomic instability and chromosomal translocations. Cells utilize two repair pathways:

Homologous Recombination (HR)

• Characteristics: High-fidelity, error-free pathway that repairs DSBs with no loss of genetic material.

• Cell Cycle Timing: Strictly restricted to the $S$ and $G_2$ phases, as it requires an intact, identical sister chromatid ($4n$ DNA content) to serve as an undamaged template.

• Mechanism Steps:

  1. DSB Sensing and Resection: The $BRCA1$ complex senses the break and promotes $5' \rightarrow 3'$ nucleolytic end resection, leaving $3'$ single-stranded DNA overhangs.

  2. Strand Invasion: $BRCA2$ mediates nucleoprotein filament assembly, facilitating homologous pairing and strand invasion of the single-stranded overhang into the adjacent undamaged sister chromatid.

  3. Synthesis and Resolution: DNA Polymerase extends the invading strand using the sister chromatid template, followed by strand displacement, junction resolution, and ligation.

• Pathology – BRCA1 / BRCA2 Mutations and Cancer:

  • Germline loss-of-function mutations in $BRCA1$ or $BRCA2$ impair Homologous Recombination, causing high rates of un-repaired double-strand breaks.

*   *BRCA1 Lifetime Risks:* Breast cancer $50\% - 65\%$ (males: $1.2\%$), Ovarian cancer $40\% - 65\%$, Prostate cancer $9\%$, Pancreatic cancer $1\% - 3\%$.
*   *BRCA2 Lifetime Risks:* Breast cancer $40\% - 55\%$ (males: up to $9\%$), Ovarian cancer $15\% - 25\%$, Prostate cancer $15\%$, Pancreatic cancer $2\% - 7\%$.

• Synthetic Lethality (PARP Inhibitors in BRCA-Mutated Cancers):

  • Tumors with homozygous loss of $BRCA1$ or $BRCA2$ ($BRCA1/2^{-/-}$) lack functional Homologous Recombination.

  • Treatment with PARP inhibitors (e.g., Olaparib) blocks Base Excision Repair, causing single-strand breaks to degenerate into double-strand breaks during replication.

  • Normal somatic cells ($BRCA1/2^{+/+}$) repair these secondary DSBs via HR and survive. In contrast, $BRCA1/2^{-/-}$ cancer cells cannot execute HR, inducing selective cell death (synthetic lethality).

Non-Homologous End-Joining (NHEJ)

• Characteristics: Rapid, error-prone pathway that directly ligates broken DNA ends without requiring a homologous template strand; results in the loss of nucleotides / genetic material at the junction site.

• Cell Cycle Timing: Operates continuously throughout all phases of the cell cycle ($G_1$, $S$, $G_2$, and $M$ phases).

• Mechanism Steps:

  1. End Binding: The $Ku70/Ku80$ heterodimer rapidly binds directly to exposed double-stranded DNA ends.

  2. Kinase Recruitment: Recruits and activates the DNA-dependent protein kinase catalytic subunit ($DNA\text{-}PK_{cs}$).

  3. Processing and Ligation: Minimal end-processing (nuclease trimming or polymerase filling) occurs, after which DNA Ligase IV ($LIG4$) directly seals the broken phosphodiester backbones.

Comparative Summary of DNA Repair Pathways